Loading...
XSHE300030
Market cap249mUSD
Dec 25, Last price  
5.69CNY
1D
-1.67%
1Q
11.57%
Jan 2017
-56.95%
IPO
58.54%
Name

GZ IMPROVE MEDICAL INSTRUMENTS CO.

Chart & Performance

D1W1MN
XSHE:300030 chart
P/E
—
P/S
2.73
EPS
—
Div Yield, %
0.91%
Shrs. gr., 5y
0.33%
Rev. gr., 5y
3.23%
Revenues
645m
-9.31%
44,121,17672,321,065103,447,988140,793,354165,866,083249,639,335304,084,984396,737,493461,792,180545,348,932517,103,043549,652,842549,963,261575,061,342919,225,503799,833,986710,768,471644,621,152
Net income
-63m
8,344,55213,190,02320,462,03626,905,04029,020,72135,674,85537,472,26046,119,86353,057,20839,835,20930,477,44011,158,462026,024,206162,515,16318,568,5290-63,203,837
CFO
80m
+88.11%
6,570,9942,651,19824,764,33333,034,20928,855,39838,862,92036,062,20444,381,2530023,185,032142,192,98056,036,17749,162,409141,274,052171,738,97242,478,05879,904,932
Dividend
Jul 06, 20220.04 CNY/sh
Earnings
May 21, 2025

Profile

Improve Medical Instruments Co., Ltd. provides technologies, products, and services for clinical laboratory and clinical nursing in China and internationally. Its principal products include IMPROVACUTER evacuated blood collection systems, IMPROMINI capillary blood collection systems, IMPROSWAB microbiological transportation systems, IMPRONURSE infusion pumps and syringe pumps, LONGX urine analysis systems, in-vitro diagnostic reagents, etc. The company also provides blood collection needles, pulsewave blood pressure monitors, thrombosis viscoelastic analysis systems, feces analysis systems, blood collection tube preparation systems, graphic user interface devices, intelligent sorters, multi-function blood collection tables, intelligent queue systems, urine collection tube preparation systems, automatic tube packer systems, and consumable labels. The company was formerly known as Guangzhou Improve Medical Instruments Co., Ltd. Improve Medical Instruments Co., Ltd. was founded in 1996 and is headquartered in Guangzhou, China.
URL
https://www.improve-medical.com/
IPO date
Dec 25, 2009
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
644,621
-9.31%
710,768
-11.14%
799,834
-12.99%
Cost of revenue
609,270
654,900
663,084
Unusual Expense (Income)
NOPBT
35,352
55,869
136,750
NOPBT Margin
5.48%
7.86%
17.10%
Operating Taxes
17,158
4,072
Tax Rate
48.54%
2.98%
NOPAT
18,194
55,869
132,678
Net income
(63,204)
 
18,569
-88.57%
Dividends
(15,938)
(12,367)
(9,881)
Dividend yield
0.65%
0.58%
0.30%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
353,789
394,235
478,631
Long-term debt
16,992
38,618
63,903
Deferred revenue
36,516
58,649
63,152
Other long-term liabilities
6,133
4,001
1,300
Net debt
(96,350)
(52,335)
(131,442)
Cash flow
Cash from operating activities
79,905
42,478
171,739
CAPEX
(43,702)
Cash from investing activities
(38,504)
Cash from financing activities
(50,092)
FCF
123,020
106,521
129,566
Balance
Cash
237,714
224,046
345,741
Long term investments
229,417
261,143
328,235
Excess cash
434,900
449,651
633,985
Stockholders' equity
315,542
426,139
635,953
Invested Capital
854,723
875,274
973,573
ROIC
2.10%
6.04%
13.17%
ROCE
3.01%
4.28%
8.47%
EV
Common stock shares outstanding
316,019
309,187
309,187
Price
7.75
12.48%
6.89
-34.94%
10.59
-13.19%
Market cap
2,449,149
14.97%
2,130,301
-34.94%
3,274,268
-13.08%
EV
2,392,044
2,114,228
3,173,062
EBITDA
84,009
102,619
190,064
EV/EBITDA
28.47
20.60
16.69
Interest
16,564
19,699
25,441
Interest/NOPBT
46.86%
35.26%
18.60%